B. Riley Predicts Harrow’s Q1 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Analysts at B. Riley lowered their Q1 2025 earnings estimates for Harrow in a report released on Monday, March 31st. B. Riley analyst M. Mamtani now expects that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.15. B. Riley currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s FY2025 earnings at $0.78 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $4.79 EPS.

Harrow (NASDAQ:HROW) last released its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $57.00 target price on shares of Harrow in a research report on Monday, March 31st.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $23.52 on Thursday. The firm has a market cap of $838.58 million, a price-to-earnings ratio of -25.02 and a beta of 0.46. Harrow has a 1 year low of $9.86 and a 1 year high of $59.23. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The business has a fifty day simple moving average of $27.98 and a 200 day simple moving average of $37.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Braidwell LP increased its position in Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company’s stock worth $30,431,000 after buying an additional 467,401 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after acquiring an additional 194,480 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after acquiring an additional 166,602 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Harrow by 483.2% in the 4th quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock valued at $5,044,000 after acquiring an additional 124,574 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its holdings in Harrow by 128.0% in the 4th quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company’s stock worth $6,728,000 after purchasing an additional 112,588 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.